Real-time enrollment status for this relapsed/refractory acute myeloid leukemia clinical trial
Current Status
Recruiting
Checked: August 27, 2026 at 8:37 AM UTC
| NCT Number | NCT06714591 |
| Recruiting Status | Recruiting |
| Condition | Relapsed/Refractory Acute Myeloid Leukemia |
| Phase | PHASE1 |
| Target Enrollment | 120 participants |
| Active Locations | 18 sites in the US |
| Sponsor | SystImmune Inc. |
| Last Updated on CT.gov | July 21, 2026 (Jul 21, 2026) |
As of August 27, 2026: Clinical trial NCT06714591 is currently recruiting participants. This phase1 study for relapsed/refractory acute myeloid leukemia is actively seeking new participants at 18 locations across the United States. The study is sponsored by SystImmune Inc.. This status information is automatically verified from the official ClinicalTrials.gov registry.
Yes, NCT06714591 is actively recruiting participants as of August 27, 2026. You can check eligibility and apply through HelloStudys.
This trial is recruiting at 18 locations in the United States. View all available locations on the full study page.
Check your eligibility and express interest by completing the application form on the study page. A research coordinator will follow up to discuss next steps.
The official ClinicalTrials.gov record for NCT06714591 was last updated Jul 21, 2026 (July 21, 2026). HelloStudys verifies this status automatically.